Evidence map›Paper›PMID 25834071›Full record

ArticleAmerican journal of physiology. Renal physiology2015

Platelets are relevant mediators of renal injury induced by primary endothelial lesions.

Claudia Schwarzenberger, Jan Sradnick, Kenneth M Lerea, Michael S Goligorsky, Bernhard Nieswandt, Christian P M Hugo, Bernd Hohenstein

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Renal physiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Review
  7. The role of platelets in acute kidney injury.Nature reviews. Nephrology · 2018
    Review
  8. Article
  9. Observational
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Claudia SchwarzenbergerDivision of Nephrology, Department of Internal Medicine III, Technische Universitaet Dresden, Dresden, Germany;
Jan SradnickDivision of Nephrology, Department of Internal Medicine III, Technische Universitaet Dresden, Dresden, Germany;
Kenneth M LereaDepartment of Cell Biology and Anatomy, New York Medical College, Valhalla, New York;
Michael S GoligorskyRenal Research Institute, New York Medical College, Valhalla, New York; and.
Bernhard NieswandtRudolf Virchow Center, DFG Research Center for Experimental Biomedicine, University of Wuerzburg, Wuerzburg, Germany.
Christian P M HugoDivision of Nephrology, Department of Internal Medicine III, Technische Universitaet Dresden, Dresden, Germany;
Bernd HohensteinDivision of Nephrology, Department of Internal Medicine III, Technische Universitaet Dresden, Dresden, Germany; bernd.hohenstein@uniklinikum-dresden.de.
TU Dresden · DENew York Medical College · USUniversity of Würzburg · DE

Funding

RENAL ENDOTHELIAL AND SMOOTH MUSCLE CELLS INTERACTIONSR01DK045462 · NIDDK · STATE UNIVERSITY NEW YORK STONY BROOK · PI GOLIGORSKY, MICHAEL S · 1995 to 2014
$4.8M
VASCULAR PERMEABILITY IN DIABETIC NEPHROPATHYR01DK054602 · NIDDK · STATE UNIVERSITY NEW YORK STONY BROOK · PI GOLIGORSKY, MICHAEL S · 1999 to 2010
$2.5M
Endothelial dysfunction in acute renal ischemiaR01DK052783 · NIDDK · STATE UNIVERSITY NEW YORK STONY BROOK · PI GOLIGORSKY, MICHAEL S · 1997 to 2007
$2.0M
NIDDK NIH HHS DK-052783NIDDK NIH HHS DK-45462NIDDK NIH HHS DK-54602
6 · The paper itself

Abstract

Several studies have suggested a prominent (pro)inflammatory and harmful role of platelets in renal disease, and newer work has also demonstrated platelet release of proangiogenic factors. In the present study, we investigated the role of platelets in a mouse model of selective endothelial cell injury using either platelet depletion or the pharmacological P2Y12 receptor blocker clopidogrel as an interventional strategy. The concanavalin A/anti-concanavalin A model was induced in left kidneys of C57bl/6J wild-type mice after initial platelet depletion or platelet-inhibiting therapy using clopidogrel. FACS analysis of glycoprotein IIb/IIIa/P-selectin double-positive platelets and platelet-derived microparticles demonstrated relevant platelet activation after the induction of selective endothelial injury in mice. Enhanced platelet activation persisted for 5 days after disease induction and was accompanied by increased amounts of circulating platelet-derived microparticles as potential mediators of a prolonged procoagulant state. By immunohistochemistry, we detected significantly reduced glomerular injury in platelet-depleted mice compared with control mice. In parallel, we also saw reduced endothelial loss and a consequently reduced repair response as indicated by diminished proliferative activity. The P2Y12 receptor blocker clopidogrel demonstrated efficacy in limiting platelet activation and subsequent endothelial injury in this mouse model of renal microvascular injury. In conclusion, platelets are relevant mediators of renal injury induced by primary endothelial lesions early on, as demonstrated by platelet depletion as well as platelet inhibition via the P2Y12 receptor. While strategies to prevent platelet-endothelial interactions have shown protective effects, the contribution of platelets during renal regeneration remains unknown.

Indexed as

Platelet ActivationAcute Kidney InjuryAnimalsBlood PlateletsCell-Derived MicroparticlesClopidogrelDisease Models, AnimalEndothelial CellsEndothelium, VascularMaleMice, Inbred C57BLP-SelectinTiclopidineClopidogrelP-SelectinTiclopidineclopidogrelplatelet microparticlesplateletsrenal microvascular endothelial injurythrombotic microangiopathy

Identifiers

PMID25834071
PMCPMC4451331
OpenAlexW2084034564

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.